Alnylam licenses intellectual property in RNA interference.
Alnylam executed a co-exclusive therapeutic license from Stanford University for the RNA interference patent application and related technology which is based on the research of Dr. Mark Kay, Dr. Anton McCaffrey and colleagues at the Stanford University School of Medicine. This intellectual property encompasses the demonstration that delivery of synthetic small interfering RNA molecules to an adult mammal can induce in vivo silencing of a specific target gene, thereby a basis for the systemic administration of RNAi-based therapies in mammals.
"The addition of this intellectual property from Stanford, when combined with our existing portfolio of the fundamental patents in the field of RNAi, further strengthens Alnylam's clear leadership in worldwide intellectual property for the development of RNAi-based therapeutics," said Dr. John Maraganore, president and CEO of Alnylam. "We continue to fortify our intellectual property foundation in RNAi that uniquely positions us to develop and commercialize a new class of medicines."
Alnylam is a leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health. Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals, and Ribopharma (Kulmbach, Germany). Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders.
Alnylam Pharmaceuticals, Inc.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||to Stanford University|
|Comment:||Alnylam licenses intellectual property in RNA interference.(to Stanford University)|
|Publication:||BIOTECH Patent News|
|Date:||Sep 1, 2003|
|Previous Article:||Generex Biotechnology announces grant of European patent for aerosol delivery.|
|Next Article:||Cambridge Antibody and Dyax amend antibody product agreement.|